Reward mechanisms in obesity: new insights and future directions
Hobart says that shouldnt be a patients only priority
Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria
SCFA may stimulate the release of GLP-1 by binding to the L-cell receptors
"Weight loss rarely happens fast enough through diet and exercise alone to cause this." Casselman's dilemma is another aspect of the ways these agonists , which experts say are on track to become the most profitable drugs of the 21st century, are impacting social, personal, and economic life in America
Am J Pathol (2020) 190(2):40011